Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.

ABSTRACT:

Introduction

Since the first COVID-19 messenger RNA vaccines became available globally for emergency or conditional use, post-marketing surveillance activities have been implemented for the monitoring of any adverse events that might arise in daily clinical practice and were not detected earlier during clinical trials.

Methods

Safety data concerning the BNT162b2 and the mRNA-1273 COVID-19 vaccines were collected from the Vaccine Adverse Event Reporting System (VAERS) for the period from December 2020 to October 15, 2021. In addition to a descriptive analysis of individuals who experienced an adverse event after vaccination, a case-non-case analysis was performed by using the Reporting Odds Ratio with 95 % confidence interval as statistical parameter for detecting differences

SUBMITTER: Santi Laurini G 

PROVIDER: S-EPMC10043970 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature